Compare Ascendis Pharma A/S (ASND) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Hilton Hotels Corporation Common Stock — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Hilton Hotels Corporation Common Stock trades at $335.87 (market cap $76.37B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 4.3× Ascendis Pharma A/S's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HLT | |
|---|---|---|
Market Cap | $17.74B | $76.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $350.22 |
52-Week Low | $163.32 | $256.75 |
Enterprise Value | $18.11B | $88.87B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Hilton Worldwide (HLT) trades at $335.48, down 0.64% on the day, with a bullish technical signal and strong earnings beat history. Revenue grew to $12.04B in 2025 with a net income margin of 12.56%, though valuation multiples appear elevated with a P/E of 51.22. Recent news highlights brand campaigns and property renovations, supporting positive sentiment.
Outlook remains favorable with analyst consensus price target of $342.11 implying modest upside. Risks include high debt levels and sensitivity to travel demand fluctuations. The stock offers growth exposure to hospitality recovery but requires monitoring of leverage and macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
